<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-146-284</article-id>
<article-id pub-id-type="doi">10.26800/LV-146-7-8-5</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group>
</article-categories>
<title-group>
<article-title>24-satni profili krvnog tlaka u bolesnika s bole&#x0161;&#x0107;u bubrega &#x2013; iskustvo jednog centra</article-title>
<trans-title-group xml:lang="en">
<trans-title>Blood pressure phenotypes defined by ambulatory blood pressure monitoring in patients with chronic kidney disease &#x2013; single-center experience</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5640-1474</contrib-id><name><surname>Herenda</surname><given-names>Vedad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rebi&#x0107;</surname><given-names>Damir</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hasanspahi&#x0107;</surname><given-names>Senad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hamzi&#x0107;-Mehmedba&#x0161;i&#x0107;</surname><given-names>Aida</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ribi&#x0107;-Mrkonja</surname><given-names>Azra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Odoba&#x0161;i&#x0107;</surname><given-names>Merima</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label>Klinika za nefrologiju, Klini&#x010D;ki centar Univerziteta u Sarajevu, Sarajevo, Bosna i Hercegovina</aff>
<aff id="aff2"><label>2</label>Medicinski fakultet Univerziteta u Sarajevu, Sarajevo, Bosna i Hercegovina</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Mr. sc. Vedad Herenda, dr. med., <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-5640-1474">https://orcid.org/0000-0002-5640-1474</ext-link>, Klinika za nefrologiju, Klini&#x010D;ki centar Univerziteta u Sarajevu, Bolni&#x010D;ka 25, 71000 Sarajevo, Bosna i Hercegovina, e-po&#x0161;ta: <email xlink:href="vedad.herenda@gmail.com">vedad.herenda@gmail.com</email></corresp>
<fn fn-type="con">
<p content-type="fn-title">DOPRINOS AUTORA</p>
<p>K<sc>oncepcija</sc> <sc>ili</sc> <sc>nacrt</sc> <sc>rada</sc>: VH, DR</p>
<p>P<sc>rikupljanje</sc>, <sc>analiza</sc> <sc>i</sc> <sc>interpretacija</sc> <sc>podataka</sc>: VH, SH, AHM, ARM, MO</p>
<p>P<sc>isanje</sc> <sc>prve</sc> <sc>verzije</sc> <sc>rada</sc>: VH, DR, SH</p>
<p>K<sc>riti&#x010D;ka</sc> <sc>revizija</sc>: DR, AHM</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>08</month><year>2024</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>08</month><year>2024</year></pub-date>
<volume>146</volume>
<issue>7-8</issue>
<fpage>284</fpage>
<lpage>290</lpage>
<permissions>
<copyright-statement>Croatian Medical Association</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<sec><title>Uvod</title><p>Ovisno o rezultatima ambulantnog pra&#x0107;enja krvnog tlaka (ABPM), pacijenti imaju razli&#x010D;ite profile krvnog tlaka, a neke velike me&#x0111;unarodne studije poku&#x0161;ale su ispitati i usporediti profil kontinuiranog monitoringa krvnog tlaka (KMAT) pacijenata u razli&#x010D;itim zemljama. U na&#x0161;oj studiji poku&#x0161;ali smo utvrditi profile arterijske hipertenzije na&#x0161;ih pacijenata.</p></sec>
<sec><title>Materijali i metode</title><p>Ovo je retrospektivna studija presjeka od listopada 2022. do travnja 2023. Ispitani su demografski, klini&#x010D;ki i podatci o 24-satnom krvnom tlaku. Bolesnici su podijeljeni u nekoliko kategorija prema fenotipovima hipertenzije i <italic>dipping</italic> profilima. Analize su provedene koriste&#x0107;i mjere deskriptivne statistike.</p></sec>
<sec><title>Rezultati</title><p>U studiju su bila uklju&#x010D;ena 94 bolesnika. Tijekom pra&#x0107;enja 12 pacijenata je umrlo. Hipertenzija bijele kute bila je naj&#x010D;e&#x0161;&#x0107;i fenotip hipertenzije u na&#x0161;ih bolesnika (30,8%), a druga najve&#x0107;a skupina bila je trajna nekontrolirana hipertenzija (29,7%). Tako&#x0111;er, prona&#x0161;li smo visoku prevalenciju <italic>non-dippers</italic> sistoli&#x010D;kog (43,6%) i obrnutog <italic>dipper</italic> dijastoli&#x010D;kog tlaka (42,5%). Rezultati pokazuju visoko zna&#x010D;ajne razlike izme&#x0111;u skupine koja je bila &#x017E;iva i skupine koja je umrla, s p &lt; 0,001, &#x0161;to ukazuje da je profil krvnog tlaka povezan s ishodima pre&#x017E;ivljenja.</p></sec>
<sec><title>Zaklju&#x010D;ci</title><p>Prevalencija visokorizi&#x010D;nog profila povi&#x0161;enoga krvnog tlaka u bubre&#x017E;nih bolesnika je visoka. Zbog povi&#x0161;enoga no&#x0107;nog krvnog tlaka u lije&#x010D;enju samo pra&#x0107;enje krvnog tlaka nije dovoljno. KMAT bi trebao postati zlatni standard za potvrdu odgovaraju&#x0107;e kontrole krvnog tlaka u bolesnika s bole&#x0161;&#x0107;u bubrega.</p></sec>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<sec><title>Background</title><p>Depending on results of ambulatory blood pressure monitoring (ABPM) patients have different hypertension profiles and some large international studies tried to examine and compare ABPM profile of patients in different countries. In our study we tried to establish hypertension profiles of our patients.</p></sec>
<sec><title>Materials and methods</title><p>This is retrospective, cross-sectional study from October 2022 to April 2023. Demographic, clinical and 24-hour ambulatory blood-pressure data were examined. Patients were divided in several categories according to their hypertension phenotypes and dipping profiles. Analyses were conducted with descriptive statistics.</p></sec>
<sec><title>Results</title><p>94 patients were included in study. During follow up 12 patients died. White-coat hypertension was the most common hypertension phenotype in our patients 30.8%, the second largest group was sustained uncontrolled hypertension (29.7%). Also, we have found high prevalence of non-dippers systolic (43.6%) and reverse dipper diastolic (42.5%). The results shows highly significant differences between group who was alive and group who died, with having p &lt; 0.001, which indicates that the dipping status of blood pressure is associated with the survival outcomes.</p></sec>
<sec><title>Conclusions</title><p>The prevalence of high-risk BP profile in renal patients is high. Due to elevated nocturnal BP clinic BP monitoring alone is inadequate. ABPM should become golden standard to confirm adequate BP control in patients with kidney disease.</p></sec>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori KONTINUIRANO MJERENJE KRVNOG TLAKA &#x2013; statisti&#x010D;ki podatci</kwd><kwd>HIPERTENZIJA &#x2013; dijagnoza, epidemiologija, komplikacije</kwd><kwd>HIPERTENZIJA BIJELE KUTE &#x2013; dijagnoza, epidemiologija</kwd><kwd>MASKIRANA HIPERTENZIJA &#x2013; dijagnoza, epidemiologija</kwd><kwd>KRONI&#x010C;NA BUBRE&#x017D;NA BOLEST &#x2013; komplikacije, smrtnost</kwd><kwd>FENOTIP</kwd><kwd>PROGNOZA</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>BLOOD PRESSURE MONITORING, AMBULATORY &#x2013; statistics and numerical data</kwd><kwd>HYPERTENSION &#x2013; complications, diagnosis, epidemiology</kwd><kwd>WHITE COAT HYPERTENSION &#x2013; diagnosis, epidemiology</kwd><kwd>MASKED HYPERTENSION &#x2013; diagnosis, epidemiology</kwd><kwd>RENAL INSUFFICIENCY, CHRONIC &#x2013; complications, mortality</kwd><kwd>PHENOTYPE</kwd><kwd>PROGNOSIS</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Arterijska hipertenzija je vode&#x0107;i &#x010D;imbenik rizika za kroni&#x010D;ne nezarazne bolesti u svijetu. Povi&#x0161;en krvni tlak jest i jedan od uzroka kroni&#x010D;noga bubre&#x017E;nog zatajenja (KBZ), ali i njegova &#x010D;esta posljedica. S napredovanjem bubre&#x017E;nog zatajenja napreduje i broj onih koji imaju hipertenziju, tako da se procjenjuje da povi&#x0161;eni arterijski tlak ima 85% oboljelih od KBZ-a, ra&#x010D;unaju&#x0107;i na sve stadije bolesti. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) U populaciji oboljelih od KBZ-a prevalencija rezistentne hipertenzije ve&#x0107;a je dva do tri puta u odnosu na bolesnike bez bubre&#x017E;ne bolesti. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Kontinuirani monitoring krvnog tlaka (KMAT) najbolja je metoda za otkrivanje rizika od &#x0161;tetnih ishoda povezanih s hipertenzijom. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) U bubre&#x017E;nih bolesnika KMAT ima i prognosti&#x010D;ku ulogu glede ishoda bolesti. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>)</p>
<p>Ovisno o rezultatima KMAT-a pacijenti imaju razli&#x010D;ite profile arterijskog tlaka i neke velike me&#x0111;unarodne studije poku&#x0161;ale su ispitati i usporediti ove profile. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) Tako&#x0111;er su provedene studije koje su utvrdile razliku izme&#x0111;u profila hipertenzije kod pacijenata s kroni&#x010D;nom bubre&#x017E;nom bole&#x0161;&#x0107;u (KBB) iz razli&#x010D;itih zemalja. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>)</p>
<p>U na&#x0161;em istra&#x017E;ivanju poku&#x0161;ali smo utvrditi profile hipertenzije na&#x0161;ih pacijenata s kroni&#x010D;nom bubre&#x017E;nom bole&#x0161;&#x0107;u i bez nje, kao i prisutnost i osobitosti 24-satnih varijacija &#x2013; <italic>dipping</italic> status.</p>
<sec sec-type="other1">
<title>Materijal i metode</title>
<p>Ovo je retrospektivna presje&#x010D;na studija provedena od listopada 2022. do svibnja 2023. godine. Ispitivani su demografski, laboratorijski, klini&#x010D;ki i 24-satni ambulantni podatci o krvnom tlaku 104 odraslih bolesnika hospitaliziranih na Klinici za nefrologiju KCUS-a.</p>
<p>Krvni tlak je mjeren tri puta u toku studije slijede&#x0107;i preporuke Europskog dru&#x0161;tva za hipertenziju iz 2021. godine za bolni&#x010D;ko i vanbolni&#x010D;ko mjerenje arterijskog tlaka. Prvi put je mjeren prilikom prijma pacijenta na bolni&#x010D;ko lije&#x010D;enje kori&#x0161;tenjem standardiziranoga aneroidnog sfingmomanometra, model <italic>Bosso Clinicus II</italic>, nakon prethodnog odmora u sjede&#x0107;em polo&#x017E;aju pet minuta. Drugo mjerenje je bilo tijekom bolni&#x010D;kog lije&#x010D;enja kori&#x0161;tenjem validiranoga oscilometrijskoga automatskog sredstva <italic>Boso TM-2450</italic>, koje je mjerilo tlak u danu tijekom 30 minuta i no&#x0107;u tijekom sat vremena. Dnevna i no&#x0107;na mjerenja iznosila su po 12 sati tijekom 24 sata. Minimalno 70% izmjerenih vrijednosti moralo je biti ispravno kako bi nalaz bio uzet u razmatranje. Kori&#x0161;tena je man&#x0161;eta za ruku odgovaraju&#x0107;e &#x0161;irine. Od ispitanika je tra&#x017E;eno da vode pisanu evidenciju dnevnih aktivnosti. Tre&#x0107;e mjerenje krv-</p>
<p>nog tlaka bilo je tri mjeseca nakon otpusta s Klinike. Ukupno 94 bolesnika imala su adekvatno izmjerene vrijednosti KMAT-a i povijesti bolesti podobne za uklju&#x010D;enje u studiju.</p>
<p>Fenotipovi hipertenzije kod lije&#x010D;enih pacijenata definirani su kao nekontrolirana hipertenzija bijele kute (klini&#x010D;ki sistoli&#x010D;ki krvni tlak &#x2265;140 mm Hg ili dijastoli&#x010D;ki &#x2265;90 mm Hg i 24-satni sistoli&#x010D;ki tlak &lt;130 mm Hg i dijastoli&#x010D;ki &lt;80 mm Hg), maskirna nekontrolirana hipertenzija (klini&#x010D;ki sistoli&#x010D;ki tlak &lt;140 mm Hg i dijastoli&#x010D;ki &lt;90 mm Hg i 24-satni sistoli&#x010D;ki tlak &#x2265;130 mm Hg ili dijastoli&#x010D;ki &#x2265;80 mm Hg), trajna nekontrolirana hipertenzija (klini&#x010D;ki sistoli&#x010D;ki tlak &#x2265;140 mm Hg ili dijastoli&#x010D;ki &#x2265;90 mm Hg i ambulantni 24-satni sistoli&#x010D;ki tlak &#x2265;130 mm Hg ili dijastoli&#x010D;ki &#x2265;80 mm Hg), ili kontrolirana hipertenzija kod lije&#x010D;enih odnosno normotenzija kod zdravih (klini&#x010D;ki sistoli&#x010D;ki tlak &lt;140 mm Hg i dijastoli&#x010D;ki &lt;90 mm Hg i 24-satni sistoli&#x010D;ki tlak &lt;130 mm Hg i dijastoli&#x010D;ki &lt;80 mm Hg).</p>
<p>Razlike u vrijednosti dnevnog i no&#x0107;nog tlaka &#x2013; <italic>dipping</italic> status bile su definirane kao: <italic>dipper</italic> (kada je no&#x0107;ni sistoli&#x010D;ki i dijastoli&#x010D;ki pad tlaka bio 10 &#x2013; 20% tijekom spavanja), <italic>non-dippers</italic> (kada je no&#x0107;ni pad bio</p>
<p>&lt;10% ili bez sni&#x017E;enja no&#x0107;noga srednjeg tlaka), reverzni <italic>dipper</italic> (ako je dolazilo do porasta krvnog tlaka tijekom no&#x0107;i) te ekstremni <italic>dipper</italic> (ako su vrijednosti pada krvnog tlaka bile vi&#x0161;e od 20%).</p>
<p>Proteinurija je podijeljena na normalnu, umjerenu i te&#x0161;ku. Proteinurija je odre&#x0111;ivana turbidimetrijskom metodom na aparatu <italic>Roche/Hitachi cobas c 503</italic>.</p>
<p>Statisti&#x010D;ka analiza je provedena kori&#x0161;tenjem programa <italic>IBM SPSS Statistics 29.0</italic>. Statisti&#x010D;ka zna&#x010D;ajnost je bila odre&#x0111;ena p-vrijedno&#x0161;&#x0107;u &#x2264;0,05. Deskriptivne metode su koristile srednju vrijednost i standardnu devijaciju (SD) za kontinuirane podatke i frekvencije i postotke za kategorijske podatke. Tablice su kori&#x0161;tene kao sredstva za vizualizaciju.</p>
</sec>
<sec sec-type="other2">
<title>Rezultati</title>
<p>Ukupno je bilo 94 ispitanika, uklju&#x010D;uju&#x0107;i one koji su bili &#x017E;ivi na kraju studije (82 pacijenta) i one koji su umrli tijekom pra&#x0107;enja (12 pacijenata). U studiji je ispitivano 46 (48,9%) mu&#x0161;karaca i 48 (51,1%) &#x017E;ena. Prosje&#x010D;na dob ispitanika bila je 58,7&#x00B1;14,0. Tijekom studije umrlo je 12 ispitanika prosje&#x010D;ne dobi 71,2&#x00B1;8,12 godina. Prosje&#x010D;na dob ispitanika koji su bili &#x017E;ivi na kraju studije bila je 56,8&#x00B1;13,8 godina. Srednja vrijednost klini&#x010D;koga sistoli&#x010D;kog tlaka iznosila je 146,56&#x00B1;27,6 mmHg, a klini&#x010D;koga dijastoli&#x010D;kog tlaka 85,9&#x00B1;14,6 mmHg. Karateristike ispitivane populacije su nazna&#x010D;ene u <xref ref-type="table" rid="t1">Table 1</xref>.</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Karakteristike ispitivane populacije / Characteristics of study cohort</title>
</caption>
<table frame="hsides" rules="groups">
<col width="41.44%"/>
<col width="11.24%"/>
<col width="18.93%"/>
<col width="17.15%"/>
<col width="11.24%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Karakteristike<break/>Characteristics</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Svi pacijenti<break/>/ All patients<break/>(N=94)</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Pacijenti koji su bili bili &#x017E;ivi na kraju studije<break/>/ Patients alive at the end of study<break/>(N=82)</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Pacijenti koji su umrli tijekom studije<break/>/ Patients who died during follow-up<break/>(N=12)</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">p-vrijednost<break/>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Spol &#x2013; no (%) / Gender &#x2013; no (%)<break/>&#x00A0;&#x00A0;Mu&#x0161;ki / Male<break/>&#x00A0;&#x00A0;&#x017D;enski / Female</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">46 (48,9)<break/>48 (51,1)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">42 (51,2)<break/>40 (48,7)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4 (30,8)<break/>8 (61,5)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&lt;0,001<break/>&lt;0,001</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Dob &#x2013; godine / Sex &#x2013; yrs</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">58,7&#x00B1;14,0</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">56,8&#x00B1;13,8</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">71,2&#x00B1;8,12</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,000</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="col">Kroni&#x010D;ne bolesti / Chronic diseases</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt"></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">&#x00A0;&#x00A0;Kroni&#x010D;no bubre&#x017E;no zatajenje &#x2013; no (%)<break/>&#x00A0;&#x00A0;/ Chronic kidney disease &#x2013; no (%)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">70 (74,4)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">59 (71,9)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">12 (92,3)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&lt;0,001</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">&#x00A0;&#x00A0;Arterijska hipertenzija &#x2013; no (%)<break/>&#x00A0;&#x00A0;/ Arterial hypertension &#x2013; no (%)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">84 (89,3)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">73(89,0)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">11(84,6)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,775</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">&#x0160;e&#x0107;erna bolest &#x2013; no (%) / Diabetes mellitus &#x2013; no (%)<break/>&#x00A0;&#x00A0;Proteinurija / Proteinuria<break/>&#x00A0;&#x00A0;Stadij KBZ-a &#x2013; no (%) / CKD stage &#x2013; no (%)<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;Normalna funkcija / Normal function<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stadij 1 / Stage 1<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stadij 2 / Stage 2<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stadij 3 / Stage 3<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stadij 4 / Stage 4<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stadij 5 / Stage 5</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">23 (24,4)<break/>3,80&#x00B1;7,13<break/>24 (25,5)<break/>0 (0,0)<break/>6 (6,3)<break/>17 (18,0)<break/>10 (10,6)<break/>37 (39,3)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">18 (21,9)<break/>2,63&#x00B1;4,21<break/>24 (29,2)<break/>0 (0,0)<break/>6 (7,31)<break/>14 (17,0)<break/>9 (10,9)<break/>29 (35,3)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">5 (38,5)<break/>8,23&#x00B1;10,4<break/>0 (0,0)<break/>0 (0,0)<break/>0 (0,0)<break/>3 (25,0)<break/>1(8,33)<break/>8 (66,6)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,110<break/>0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Krvni tlak &#x2013; mmHg / Blood pressure &#x2013; mmHg<break/>&#x00A0;&#x00A0;Klini&#x010D;ki sistoli&#x010D;ki / Clinical systolic<break/>&#x00A0;&#x00A0;Klini&#x010D;ki dijastoli&#x010D;ki / Clinical diastolic<break/>&#x00A0;&#x00A0;24-satni sistoli&#x010D;ki / 24 hr systolic<break/>&#x00A0;&#x00A0;24-satni dijastoli&#x010D;ki / 24 hr diastolic<break/>&#x00A0;&#x00A0;Dnevni sistoli&#x010D;ki / Daytime systolic<break/>&#x00A0;&#x00A0;Dnevni dijastoli&#x010D;ki / Daytime diastolic<break/>&#x00A0;&#x00A0;No&#x0107;ni sistoli&#x010D;ki / Nighttime systolic<break/>&#x00A0;&#x00A0;No&#x0107;ni dijastoli&#x010D;ki / Nighttime diastolic</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">146,56&#x00B1;27,6<break/>85,9&#x00B1;14,6<break/>143,4&#x00B1;103,4<break/>78,4&#x00B1;11,7<break/>142,4&#x00B1;104,2<break/>78,3&#x00B1;12,19<break/>131,2&#x00B1;18,2<break/>77,4&#x00B1;12,75</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">147,16&#x00B1;28,1<break/>86,5&#x00B1;14,3<break/>132,2&#x00B1;16,2<break/>79,2&#x00B1;11,9<break/>143,4&#x00B1;111,5<break/>79,0&#x00B1;12,5<break/>130,6&#x00B1;17,5<break/>78,0&#x00B1;13,05</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">142,5&#x00B1;25,18<break/>83,7&#x00B1;14,9<break/>218,7&#x00B1;282,7<break/>73,31&#x00B1;8,6<break/>135,7&#x00B1;20,6<break/>73,3&#x00B1;8,62<break/>135,2&#x00B1;22,7<break/>73,34&#x00B1;10,0</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,580<break/>0,530<break/>0,006<break/>0,104<break/>0,812<break/>0,128<break/>0,411<break/>0,236</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Fenotip arterijskog tlaka &#x2013; no (%)<break/>/ Hypertension phenotypes &#x2013; no(%)<break/>&#x00A0;&#x00A0;Normotenzivni / Normotensive<break/>&#x00A0;&#x00A0;Kontrolirana hipertenzija / Controlled hypertension<break/>&#x00A0;&#x00A0;Hipertenzija bijele kute / White-coat hypertension<break/>&#x00A0;&#x00A0;Nekontrolirana hipertenzija<break/>&#x00A0;&#x00A0;/ Sustained uncontrolled hypertension<break/>&#x00A0;&#x00A0;Maskirna nekontrolirana hipertenzija<break/>&#x00A0;&#x00A0;/ Masked sustained uncontrolled hypertension</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3 (3,19)<break/>20 (21,2)<break/>29 (30,8)<break/>25 (29,7)<break/>17 (18,0)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3 (3,65)<break/>17 (20,7)<break/>25 (30,4)<break/>22 (26,8)<break/>15 (18,2)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0 (0,00)<break/>3 (25,0)<break/>4 (33,0)<break/>3 (25,0)<break/>2 (16,6)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">p&gt;0,05<break/>p&gt;0,05<break/>p&gt;0,05<break/>p&gt;0,05<break/>p&gt;0,05</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Broj lijekova za povi&#x0161;eni krvni tlak &#x2013; no (%)<break/>/ No of blood pressure medications &#x2013; no (%)<break/>&#x00A0;&#x00A0;0<break/>&#x00A0;&#x00A0;1<break/>&#x00A0;&#x00A0;&#x2265;2</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">13 (13,8)<break/>13 (13,8)<break/>68 (72,3)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">11 (13,4)<break/>12 (14,6)<break/>59 (71,9)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2 (15,4)<break/>1 (7,7)<break/>10 (83,3)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,591<break/>0,591<break/>0,591</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row"><italic>Dipping</italic> status / Dipping status<break/>&#x00A0;&#x00A0;<italic>Dipper</italic> sistoli&#x010D;ki / Dipper systolic<break/>&#x00A0;&#x00A0;<italic>Ekstra dipper</italic> sistoli&#x010D;ki / Extreme dipper systolic<break/>&#x00A0;&#x00A0;<italic>Non-dipper</italic> sistoli&#x010D;ki / Non-dipper systolic<break/>&#x00A0;&#x00A0;Reverzni <italic>dipper</italic> sistoli&#x010D;ki / Reverse dipper systolic<break/>&#x00A0;&#x00A0;<italic>Dipper</italic> dijastoli&#x010D;ki / Dipper diastolic<break/>&#x00A0;&#x00A0;<italic>Ekstra dipper</italic> dijastoli&#x010D;ki / Extreme dipper diastolic<break/>&#x00A0;&#x00A0;<italic>Non-dipper</italic> dijastoli&#x010D;ki / Non-dipper diastolic<break/>&#x00A0;&#x00A0;Reverzni <italic>dipper</italic> dijastoli&#x010D;ki / Reverse dipper diastolic</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">14 (14,8)<break/>1 (1,06)<break/>41 (43,6)<break/>38 (40,4)<break/>13 (13,8)<break/>1 (1,06)<break/>39 (41,4)<break/>40 (42,5)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">11 (13,4)<break/>1 (1,21)<break/>38 (46,3)<break/>32 (39,0)<break/>11 (13,3)<break/>1 (1,21)<break/>34 (41,4)<break/>94 (1,14)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">2 (16,6)<break/>0 (0,0)<break/>4 (33,3)<break/>6 (50,0)<break/>2 (16,6)<break/>0 (0,0)<break/>6 (50,0)<break/>4 (33,3)</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">&lt;0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001<break/>&lt;0,001</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>*</p>
<p>p-vrijednosti su za usporedbu bolesnika koji su bili &#x017E;ivi na kraju studije s onima koji su umrli tijekom pra&#x0107;enja</p>
<p>/ p - values are for the comparison of patients who were alive at the end of the study with those who died during follow up</p>
</table-wrap-foot></table-wrap>
<p>Najve&#x0107;i broj na&#x0161;ih pacijenata, 40% (37/93), imao je stadij 5 KBZ-a, dok je onih s urednom bubre&#x017E;nom funkcijom 25% (23/93). Prethodnu dijagnozu povi&#x0161;enoga krvnog tlaka imalo je 89% (83/93) ispitanih osoba.</p>
<p>U ispitivanoj grupi evidentna je zna&#x010D;ajna spola razlika: u grupi preminulih zna&#x010D;ajno je ve&#x0107;i udio &#x017E;ena me&#x0111;u umrlim pacijentima (61,5%) u odnosu na mu&#x0161;karce (30,8%). Dob preminulih ispitanika u odnosu na &#x017E;ive znatno je vi&#x0161;a (71,2 vs 56,8 godina), &#x0161;to nagla&#x0161;ava va&#x017E;nost starosti kao &#x010D;imbenika rizika. Me&#x0111;u bolestima kao zna&#x010D;ajan prediktor mortaliteta izdvaja se kroni&#x010D;no bubre&#x017E;no zatajenje, sa znatno ve&#x0107;om prevalencijom me&#x0111;u umrlima (92,3%) u odnosu na grupu koja je pre&#x017E;ivjela (71,9%). Nadalje, me&#x0111;u svim pacijentima je 24,4% imalo &#x0161;e&#x0107;ernu bolest. Rezultati pokazuju da je me&#x0111;u pacijentima koji su bili &#x017E;ivi na kraju studije 21,9% pacijenata imalo &#x0161;e&#x0107;ernu bolest, a me&#x0111;u pacijentima koji su umrli tijekom pra&#x0107;enja najve&#x0107;i postotak, njih oko 38,5%, imalo je &#x0161;e&#x0107;ernu bolest.</p>
<p>Naj&#x010D;e&#x0161;&#x0107;i fenotip arterijskog tlaka bila je hipertenzija bijele kute (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p>
<fig id="f1" position="float" fig-type="figure"><label>Figure 1</label><caption><p>Percentage of arterial hypertension phenotypes in study cohort</p></caption><graphic xlink:href="LV-146-284-f1"></graphic></fig>
<p>Prosje&#x010D;ne vrijednosti serumskog kreatinina za cijelu ispitivanu grupu bile su 396 umol/l, dok je srednja vrijednost kreatinin klirensa iznosila 27,0 (10,0 &#x2013; 81,0) ml/min. Srednja vrijednost proteinurije ispitivane grupe bila je 3,80&#x00B1;7,13 g/d. Podjela ispitanika po spolu, dobi, klirensu kreatinina i terapiji prema fenotipovima je pokazana u <xref ref-type="table" rid="t2">Table 2</xref>.</p>
<table-wrap id="t2" position="float">
<label>Table 2</label><caption><title>Distribution of study cohort by sex, age, creatinine clearance, and number of antihypertensive medications according to phenotypes</title>
</caption>
<table frame="hsides" rules="groups">
<col width="17.77%"/>
<col width="14.19%"/>
<col width="14.2%"/>
<col width="13.61%"/>
<col width="13.01%"/>
<col width="27.22%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Bijela kuta<break/>White coat hypertension</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Normotenzivni<break/>Normotensive</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Nekontrolirani<break/>Uncontrolled hypertension</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Kontrolirani<break/>Controlled hypertension</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Maskirana nekontrolirana hipertenzija<break/>Masked uncontrolled hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Dob / Age</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">59,5</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">50</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">55,68</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">58,5</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">62,4</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Spol / Sex</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x017D;/F 10 (35,7%),<break/>M 18 (64,3%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x017D;/F 3 (100%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x017D;/F 12 (48%),<break/>M 13 (52%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x017D;/F 13 (65%),<break/>M 7 (35%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x017D;/F 8 (47,1%),<break/>M 9 (52,9%)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Kreatinin klirens<break/>/ Creatinine clearance</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">45,85</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">98</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">42,04</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">39,95</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">55,43</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Lijekovi<break/>/ Medications</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">2</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">3</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">2</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">2</td>
</tr>
</tbody></table></table-wrap>
<p>Izmjerena proteinurija je pokazala visoko zna&#x010D;ajne p-vrijednosti (&lt;0,001). Usporedbom razine proteinurije izme&#x0111;u stadija KBZ-a uo&#x010D;ava se da proteinurija ima tendenciju porasta kako KBZ napreduje. Podjela proteinurije prema razli&#x010D;itim fenotipovima arterijskog tlaka je prikazana u <xref ref-type="table" rid="t3">Table 3</xref>.</p>
<table-wrap id="t3" position="float">
<label>Table 3</label><caption><title>Distribution of study cohort according to levels of proteinuria and arterial hypertension phenotypes</title>
</caption>
<table frame="hsides" rules="groups">
<col width="11.86%"/>
<col width="13.01%"/>
<col width="20.7%"/>
<col width="14.2%"/>
<col width="20.12%"/>
<col width="20.11%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Kontrolirana<break/>Controlled</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Maskirana nekontrolirana<break/>Masked uncontrolled</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Normotenzivni<break/>Normotensive</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Odr&#x017E;ana nekontrolirana<break/>Sustained uncontrolled</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Hipertenzija bijele kute<break/>Whitecoat hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Normalna<break/>/ Normal</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1 (5%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3 (17,6%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1 (33,3%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2 (8%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">2 (8%)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Umjerena<break/>/ Moderate</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">16 (80%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">12 (70,6%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1 (33,3%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">12 (48%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">21 (75%)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Te&#x0161;ka<break/>/ Severe</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">3 (15%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">2 (11,8%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">1 (33,3%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">11 (8%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">5 (17,8%)</td>
</tr>
</tbody></table></table-wrap>
<p>24-satni sistoli&#x010D;ki krvni tlak (SBP) zna&#x010D;ajno je vi&#x0161;i kod pacijenata koji su umrli (p-vrijednost = 0,006), &#x0161;to implicira da bi povi&#x0161;eni 24-satni SBP mogao biti povezan s pove&#x0107;anim rizikom od smrtnosti.</p>
<p>24-satni dijastoli&#x010D;ki krvni tlak (DBP) ne pokazuje zna&#x010D;ajnu razliku (p-vrijednost = 0,104), &#x0161;to implicira da 24-satni DBP sam po sebi mo&#x017E;da nije sna&#x017E;an prediktor mortaliteta. Prelaze&#x0107;i na dnevna i no&#x0107;na mjerenja, ova mjerenja ne pokazuju statisti&#x010D;ki zna&#x010D;ajne razlike me&#x0111;u pre&#x017E;ivjelima i umrlim pacijentima, tako da dnevni i no&#x0107;ni krvni tlak nisu bili tako sna&#x017E;no povezani s mortalitetom u ovoj kohorti.</p>
<p>U studiji je 14 ispitanika bilo kategorizirano kao &#x201E;<italic>dipper</italic> sistoli&#x010D;ki&#x201C;. U grupi pre&#x017E;ivjelih njih 13,4% bilo je okarakterizirano kao <italic>dipper</italic> sistoli&#x010D;ki, dok je me&#x0111;u umrlima 16,6% bilo okarakterizirano kao <italic>dipper</italic> sistoli&#x010D;ki. Me&#x0111;u svim pacijentima, 41 bolesnik ili 43,6%</p>
<p>od ukupnog broja kategorizirano je kao &#x201E;<italic>non-dipper</italic> sistoli&#x010D;ki&#x201C;. Me&#x0111;u tim pacijentima 38 je pre&#x017E;ivjelih (41,4%), a umrlih 4 &#x0161;to predstavlja 33% od svih umrlih pacijenata &#x0161;to je vidljivo u <xref ref-type="table" rid="t1">Table 1</xref>. Ekstremni <italic>dipper</italic> sistoli&#x010D;ki predstavlja pacijente &#x010D;iji sistoli&#x010D;ki krvni tlak pokazuje jo&#x0161; ve&#x0107;i pad tijekom no&#x0107;i u usporedbi s danom. U studiji je samo jedan bolesnik imao ovaj <italic>dipping</italic> status. Reverzni <italic>dipper</italic> sistoli&#x010D;ki predstavlja pacijente koji imaju povi&#x0161;en sistoli&#x010D;ki krvni tlak tijekom no&#x0107;i u usporedbi s danom. U ovoj studiji, 38 ispitanika ili 40,4% kategorizirano je kao rerverzni <italic>dipper</italic>. Od ovog broja njih 32 (39,0%) bilo je &#x017E;ivo na kraju pra&#x0107;enja, dok je &#x0161;est ispitanika ili 50% od svih ukupno umrlih preminulo kako je vidljivo u <xref ref-type="table" rid="t1">Table 1</xref>. Kada je rije&#x010D; o dijastoli&#x010D;kom <italic>dipping</italic> statusu, 13,8% ukupnih ispitanika je kategorizirano kao <italic>dipper</italic> dijastoli&#x010D;ki. Ekstremni <italic>dipper</italic> dijastoli&#x010D;ki imalo je oko 1,21% ispitanika. <italic>Non-dipper</italic> dijastoli&#x010D;ki imalo je 41,4% pacijenata, a 40,4% je spadalo u grupu reverznih <italic>dippera</italic> dijastoli&#x010D;kih.</p>
<p>Sve kategorije <italic>dipping</italic> statusa pokazuju visoko zna&#x010D;ajne razlike izme&#x0111;u dviju skupina pre&#x017E;ivjelih i umrlih s p &lt;0,001, &#x0161;to ukazuje da je <italic>dipping</italic> status krvnog tlaka povezan s ishodima pre&#x017E;ivljenja.</p>
<p>Kada je rije&#x010D; o analizi pojave stupnjeva KBZ-a, &#x0161;e&#x0107;erne bolesti te fenotipova hipertenzije prema spolu ispitanika zanimljivo je primijetiti da, iako i mu&#x0161;karci i &#x017E;ene pokazuju prili&#x010D;no jednaku distribuciju u ranijim fazama (stupnjeve 1 do 3), &#x010D;ini se da postoji uo&#x010D;ljiva spolna razlika u kasnijim fazama. Stupanj 4 ima ve&#x0107;i udio mu&#x0161;karaca, dok stupanj 5 ima ve&#x0107;i udio &#x017E;ena (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p>
<fig id="f2" position="float" fig-type="figure"><label>Figure 2</label><caption><p>Distribution of arterial hypertension phenotypes according to stages of chronic kidney disease</p></caption><graphic xlink:href="LV-146-284-f2"></graphic></fig>
<p>Va&#x017E;no je napomenuti da u grupi onih koji su umrli vi&#x0161;e mu&#x0161;karaca pati od fenotipa hipertenzija bijele kute. Trajna nekontrolirana hipertenzija, s druge strane, ima distribuciju koja je ravnomjernije podijeljena izme&#x0111;u mu&#x0161;karaca i &#x017E;ena, s malom dominacijom mu&#x0161;karaca me&#x0111;u onima koji imaju ovaj fenotip i jo&#x0161; su &#x017E;ivi. Vi&#x0161;e &#x017E;ena nego mu&#x0161;karaca pogo&#x0111;eno je kontroliranom hipertenzijom, me&#x0111;utim manje je ljudi preminulo s ovim stanjem. &#x010C;ini se da ti fenotipovi op&#x0107;enito razli&#x010D;ito utje&#x010D;u na mu&#x0161;karce i &#x017E;ene, pri &#x010D;emu se hipertenzija bijele kute vi&#x0161;e uo&#x010D;ava kod mu&#x0161;karaca, a kontrolirana hipertenzija vi&#x0161;e kod &#x017E;ena.</p>
</sec>
<sec sec-type="other3">
<title>Rasprava</title>
<p>U periodu od 1990. do 2018. godine kroni&#x010D;na bubre&#x017E;na bolest pomakla se kao uzrok smrti s 27. mjesta na deseto. Jedino je HIV/AIDS imao ovoliku brzinu napredovanja kao uzrok smrti u modernoj medicini. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Procjene govore da jedna od deset odraslih osoba ima kroni&#x010D;nu bubre&#x017E;nu bolest ili 10% populacije. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Povi&#x0161;eni arterijski krvni tlak, s druge strane, smatra se najra&#x0161;irenijom bole&#x0161;&#x0107;u modernog doba. Sna&#x017E;an i dokazan &#x010D;imbenik rizika za nepovoljne kardiovaskularne ishode kao i pre&#x017E;ivljenje, arterijska hipertenzija ujedno je i &#x010D;est uzrok kroni&#x010D;ne bubre&#x017E;ne bolesti. Tako&#x0111;er, ona je i posljedica bubre&#x017E;nog zatajenja. Lije&#x010D;enje hipertenzije dovodi do oporavka bubre&#x017E;ne funkcije i usporavanja njezinog propadanja. Ova dvosmjerna povezanost odavno je poznata. Uzrok hipertenzije u ovoj populaciji je multifaktorijalan. Identifikacija razli&#x010D;itih hipertenzivnih fenotipova omogu&#x0107;uje nam i prepoznavanje pacijenata koji su u grupi onih s povi&#x0161;enim rizikom.</p>
<p>Prema na&#x0161;im saznanjima, ovo je prva studija u Bosni i Hercegovini koja ima za cilj ustanoviti fenotipove hipertenzije kod bubre&#x017E;nih bolesnika kao i njihovu rasprostranjenost. Zna&#x010D;aj kori&#x0161;tenja KMAT-a u dijagnosticiranju povi&#x0161;enoga krvnog tlaka neupitan je. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>-<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Detaljno odre&#x0111;ivanje fenotipa povi&#x0161;enoga krvnog tlaka dodatno poma&#x017E;e odre&#x0111;ivanju adekvatne terapije i smanjenja polipragmazije koja je &#x010D;esta u populaciji bubre&#x017E;nih bolesnika. U kona&#x010D;nici ciljanom terapijom pove&#x0107;avamo adherentnost oboljelih namjeravaju&#x0107;i pove&#x0107;ati pre&#x017E;ivljenje.</p>
<p>Na&#x0161;om studijom ustanovili smo hipertenziju bijele kute kao naj&#x010D;e&#x0161;&#x0107;i fenotip povi&#x0161;enoga krvnog tlaka u pacijenata s kroni&#x010D;nim bubre&#x017E;nim zatajenjem. Tako&#x0111;er smo ustanovili da najve&#x0107;i broj oboljelih spada u grupu <italic>non-dippera</italic>. Ovakvi rezultati bacaju novo svjetlo na fenotip povi&#x0161;enoga krvnog tlaka u na&#x0161;oj populaciji bubre&#x017E;nih bolesnika. Hipertenzija bijele kute ranije je uo&#x010D;ena kao &#x010D;esta u Italiji i &#x0160;paniji. I-DARE studija prona&#x0161;la je ovaj fenotip kao tre&#x0107;i nazastupljeniji. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Prevalencija hipertenzije bijele kute na&#x0111;ena je u 2,3% Afroamerikanca u studiji AASK, 11% Nijemaca u studiji GCKD, 16,6% ispitanika u kineskoj studiji</p>
<p>C-STRIDE (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>), 31,7% kod talijanskih autora (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) te 33% u radu marokanskih autora (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>). Postavlja se pitanje: mo&#x017E;e li geografska diristribucija imati va&#x017E;nost u odre&#x0111;ivanju fenotipa hipertenzije? Talijanski autori prona&#x0161;li su hipertenziju bijele kute kao &#x010D;estu u bubre&#x017E;nih bolesnika (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>), a sli&#x010D;ne rezultate potvrdili su i Bangash i suradnici u svojoj metaanalizi ustanovi&#x0161;i znatno ve&#x0107;u prisutnost od o&#x010D;ekivane (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>). Na&#x0161;a studija doprinosi tezi da je hipertenzija bijele kute prevalentna u ju&#x017E;nom dijelu Europe. Obja&#x0161;njenje ovakve tvrdnje moglo bi biti me&#x0111;u ostalim sociolo&#x0161;ke, kao i kulturolo&#x0161;ke prirode podru&#x010D;ja oko Mediterana. Autori velike metaanalize hipertenziju bijele kute povezuju sa specifi&#x010D;nim tipovima li&#x010D;nosti. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Kako smo ve&#x0107; naglasili, poznavanje fenotipa hipertenzije pacijenata od krajnje je prakti&#x010D;ne va&#x017E;nosti: pretjerana medikacija hipertenzije bijele kute mo&#x017E;e dovesti do ne&#x017E;eljenih u&#x010D;inaka povezanih s terapijom. Studije koje govore o rasprostranjenosti hipertenzije bijele kute rijetke su, &#x010D;emu su doprinijele razli&#x010D;ite definicije hipertenzije bijele kute, stara i nova. U posljednjim godinama hipertenzija bijele kute smatra se zna&#x010D;ajnom zbog mogu&#x0107;nosti pojave o&#x0161;te&#x0107;enja ciljnih organa. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>) KMAT je od ogromne va&#x017E;nosti u dijagnosticiranju hipertenzije bijele kute zbog &#x010D;injenice da su hipertenzija bijele kute, <italic>non-dipping</italic> fenomen te maskirna nekontrolirana hipertenzija &#x010D;e&#x0161;&#x0107;i u kroni&#x010D;nom bubre&#x017E;nom zatajenju, &#x0161;to KMAT &#x010D;ini nu&#x017E;nim za dijagnozu hipertenzije u ovoj populaciji. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) U populaciji oboljelih od kroni&#x010D;ne bubre&#x017E;ne bolesti tre&#x0107;ina pacijenata ima pogre&#x0161;no klasificiran fenotip hipertenzije. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>)</p>
<p>Trajna nekontrolirana hipertenzija u na&#x0161;oj je studiji bila na drugom mjestu prema u&#x010D;estalosti. Broj pacijenata s ovim fenotipom hipertenzije pove&#x0107;avao se kako je napredovao stadij bubre&#x017E;nog zatajenja te je ona bila naj&#x010D;e&#x0161;&#x0107;i fenotip kod pacijenata u zavr&#x0161;nom stadiju kroni&#x010D;ne bubre&#x017E;ne bolesti. Ovakav je nalaz o&#x010D;ekivan, &#x0161;to je navo&#x0111;eno i radovima ostalih autora. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) Nadalje, u na&#x0161;oj studiji proteinurija ima tendenciju porasta kako KBZ napreduje. Upravo je porast proteinurije dokazan kao najja&#x010D;i prediktor pojave sistoli&#x010D;ke hipertenzije u nekim ranije objavljenim studijama. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>) Maskirana nekontrolirana hipertenzija je stanje gdje je pacijent normotenzivan tijekom pregleda, ali je ina&#x010D;e hipertenzivan. U radu Agarwala i suradnika ustanovljeno je da je 52% ispitanika s KBZ-om imalo maskiranu nekontroliranu hipertenziju, &#x0161;to je pak daleko vi&#x0161;e od broja koji smo mi ustanovili, jer je kod nas ovaj fenotip bio na pretposljednjem mjestu po u&#x010D;estalosti. (<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>)</p>
<p>Procjena kretanja vrijednosti krvnog tlaka tijekom no&#x0107;i pokazala je da je najve&#x0107;i broj ispitanika u na&#x0161;oj studiji spadao u grupu <italic>non-dippera</italic>, sistoli&#x010D;kih i dijastoli&#x010D;kih, &#x0161;to je u populaciji bubre&#x017E;nih bolesnika o&#x010D;ekivan nalaz. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>&#x2013;<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) Na drugom mjestu po u&#x010D;estalosti slijedili su oni koji su reverzni <italic>dipperi</italic>. Gubitak <italic>dipping</italic> fenomena bio je povezan s napredovanjem stadija kroni&#x010D;noga bubre&#x017E;nog zatajenja gdje je gubitak bubre&#x017E;ne funkcije proporcionalno pra&#x0107;en i gubitkom <italic>dipping</italic> obrasca. Tako&#x0111;er, <italic>dipping</italic> status je bio povezan s ishodima pre&#x017E;ivljenja. Naime, sve kategorije <italic>dipping</italic> statusa pokazuju visoko zna&#x010D;ajne razlike izme&#x0111;u dviju skupina pre&#x017E;ivjelih, &#x0161;to ukazuje da je <italic>dipping</italic> status krvnog tlaka povezan s ishodima pre&#x017E;ivljenja. Sli&#x010D;ne rezultate, kada je rije&#x010D; o pre&#x017E;ivljenju, imali su i kineski autori (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>), kao i istra&#x017E;iva&#x010D;i iz Italije koji su pratili veliku grupu pacijenata tijekom nekoliko godina (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>). Za razliku od talijanske studije koja je bila duljeg trajanja, na&#x0161;a je bila puno kra&#x0107;a, no rezultat govori u prilog tvrdnji da je <italic>dipping</italic> status od po&#x010D;etka povezan s pove&#x0107;anom smrtno&#x0161;&#x0107;u.</p>
<p>Ustanovljene fenotipove hipertenzije podijelili smo i ovisno o spolu, ustanoviv&#x0161;i da vi&#x0161;e mu&#x0161;karaca pati od hipertenzije bijele kute, dok je kontrolirana hipertenzija prisutnija kod &#x017E;enskog spola. Trajna nekontrolirana hipertenzija imala je blagu dominaciju mu&#x0161;karaca. Ovakva je spolna distribucija ispitanika s hipertenzijom bijele kute iznena&#x0111;uju&#x0107;a, jer je ovaj fenotip hipertenzije u najve&#x0107;em broju studija &#x010D;e&#x0161;&#x0107;i kod &#x017E;ena nego kod mu&#x0161;karaca te su na&#x0161;i nalazi suprotni ve&#x0107;ini dosada&#x0161;nji studija (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>&#x2013;<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>), ali smo suglasni s velikom studijom indijskih autora (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>).</p>
<p>Glavno ograni&#x010D;enje na&#x0161;e studije jest kratko trajanje pra&#x0107;enja bolesnika, kao i heterogenost populacije. U studiji nisu uzeti u obzir razli&#x010D;iti uzroci bubre&#x017E;ne bolesti, niti su pacijenti bili razdvojeni s obzirom na duljinu trajanja bubre&#x017E;nog zatajenja i komorbiditete.</p>
</sec>
<sec sec-type="other4">
<title>Zaklju&#x010D;ci</title>
<p>Prevalencija povi&#x0161;enoga krvnog tlaka kod bubre&#x017E;nih bolesnika je visoka. &#x010C;esta pojava <italic>non-dipping</italic> fenomena kao i maskirne hipertenzije i hipertenzije bijele kute pokazuju da samo pra&#x0107;enje krvnog tlaka nije adekvatno. KMAT bi trebao postati zlatni standard za potvrdu adekvatne kontrole krvnog tlaka kod pacijenata s bubre&#x017E;nom bole&#x0161;&#x0107;u.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p content-type="fn-title">INFORMACIJE O SUKOBU INTERESA</p>
<p>Autori nisu deklarirali sukob interesa relevantan za ovaj rad.</p>
</fn>
<fn fn-type="financial-disclosure">
<p content-type="fn-title">INFORMACIJA O FINANCIRANJU</p>
<p>Za ovaj &#x010D;lanak nisu primljena financijska sredstva.</p>
</fn>
</fn-group>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ameer</surname><given-names>OZ</given-names></name></person-group>. <article-title>Hypertension in chronic kidney disease: What lies behind the scene.</article-title> <source>Front Pharmacol</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>949260</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphar.2022.949260</pub-id><pub-id pub-id-type="pmid">36304157</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgianos</surname><given-names>PI</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group>. <article-title>Resistant hypertension in chronic kidney disease (CKD): prevalence, treatment particularities, and research agenda.</article-title> <source>Curr Hypertens Rep</source>. <year>2020</year>;<volume>22</volume>:<fpage>84</fpage>. <pub-id pub-id-type="doi">10.1007/s11906-020-01081-x</pub-id><pub-id pub-id-type="pmid">32880742</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnier</surname><given-names>M</given-names></name><name><surname>Damianaki</surname><given-names>A</given-names></name></person-group>. <article-title>Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease.</article-title> <source>Circ Res</source>. <year>2023</year>;<volume>132</volume>:<fpage>1050</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.321762</pub-id><pub-id pub-id-type="pmid">37053276</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banegas</surname><given-names>JR</given-names></name><name><surname>Ruilope</surname><given-names>LM</given-names></name><name><surname>de la Sierra</surname><given-names>A</given-names></name><name><surname>Vinyoles</surname><given-names>E</given-names></name><name><surname>Gorostidi</surname><given-names>M</given-names></name><name><surname>de la Cruz</surname><given-names>JJ</given-names></name><etal/></person-group> <article-title>Relationship between clinic and ambulatory blood-pressure measurements and mortality.</article-title> <source>N Engl J Med</source>. <year>2018</year>;<volume>378</volume>:<fpage>1509</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1712231</pub-id><pub-id pub-id-type="pmid">29669232</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drawz</surname><given-names>PE</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>De Nicola</surname><given-names>L</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Gabbai</surname><given-names>FB</given-names></name><name><surname>Gassman</surname><given-names>J</given-names></name><etal/><collab>CRIC Study Investigators</collab></person-group>. <article-title>Variations in 24-Hour BP Profiles in Cohorts of Patients with Kidney Disease around the World: The I-DARE Study.</article-title> <source>Clin J Am Soc Nephrol</source>. <year>2018</year>;<volume>13</volume>:<fpage>1348</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.13181117</pub-id><pub-id pub-id-type="pmid">29976600</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>V</given-names></name><name><surname>Garcia-Garcia</surname><given-names>G</given-names></name><name><surname>Iseki</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Naicker</surname><given-names>S</given-names></name><name><surname>Plattner</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Chronic kidney disease: global dimension and perspectives.</article-title> <source>Lancet</source>. <year>2013</year>;<volume>382</volume>:<fpage>260</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60687-X</pub-id><pub-id pub-id-type="pmid">23727169</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundstr&#x00F6;m</surname><given-names>J</given-names></name><name><surname>Bodegard</surname><given-names>J</given-names></name><name><surname>Bollmann</surname><given-names>A</given-names></name><name><surname>Vervloet</surname><given-names>MG</given-names></name><name><surname>Mark</surname><given-names>PB</given-names></name><name><surname>Karasik</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2&#x00B7;4 million patients from 11 countries: The CaReMe CKD study</article-title>. <source>Lancet Reg Health Eur</source>. <year>2022</year>;<volume>20</volume>:<elocation-id>100438</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.lanepe.2022.100438</pub-id><pub-id pub-id-type="pmid">36090671</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaul</surname><given-names>U</given-names></name><name><surname>Arambam</surname><given-names>P</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Kapoor</surname><given-names>S</given-names></name><name><surname>Swahney</surname><given-names>JPS</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Usefulness of ambulatory blood pressure measurement for hypertension management in India: the India ABPM study.</article-title> <source>J Hum Hypertens</source>. <year>2020</year>;<volume>34</volume>:<fpage>457</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1038/s41371-019-0243-6</pub-id><pub-id pub-id-type="pmid">31484988</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parati</surname><given-names>G</given-names></name><name><surname>Stergiou</surname><given-names>GS</given-names></name><name><surname>Bilo</surname><given-names>G</given-names></name><name><surname>Kollias</surname><given-names>A</given-names></name><name><surname>Pengo</surname><given-names>M</given-names></name><name><surname>Ochoa</surname><given-names>JE</given-names></name><etal/></person-group> <article-title>Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension.</article-title> <source>J Hypertens</source>. <year>2021</year>;<volume>39</volume>:<fpage>1742</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1097/HJH.0000000000002922</pub-id><pub-id pub-id-type="pmid">34269334</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velasquez</surname><given-names>MT</given-names></name><name><surname>Beddhu</surname><given-names>S</given-names></name><name><surname>Nobakht</surname><given-names>E</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Raj</surname><given-names>DS</given-names></name></person-group>. <article-title>Ambulatory blood pressure in chronic kidney disease: ready for prime time?</article-title> <source>Kidney Int Rep</source>. <year>2016</year>;<volume>1</volume>:<fpage>94</fpage>&#x2013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.ekir.2016.05.001</pub-id><pub-id pub-id-type="pmid">28164170</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>MH</given-names></name><collab>Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)</collab></person-group>. <article-title>White-coat hypertension and incident end-stage renal disease in patients with non-dialysis chronic kidney disease: results from the C-STRIDE Study.</article-title> <source>J Transl Med</source>. <year>2020</year>;<volume>18</volume>:<fpage>238</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-020-02413-w</pub-id><pub-id pub-id-type="pmid">32539728</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minutolo</surname><given-names>R</given-names></name><name><surname>Borrelli</surname><given-names>S</given-names></name><name><surname>Scigliano</surname><given-names>R</given-names></name><name><surname>Bellizzi</surname><given-names>V</given-names></name><name><surname>Chiodini</surname><given-names>P</given-names></name><name><surname>Cianciaruso</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Prevalence and clinical correlates of white coat hypertension in chronic kidney disease.</article-title> <source>Nephrol Dial Transplant</source>. <year>2007</year>;<volume>22</volume>:<fpage>2217</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfm164</pub-id><pub-id pub-id-type="pmid">17420167</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abir-Khalil</surname><given-names>S</given-names></name><name><surname>Za&#x00EE;mi</surname><given-names>S</given-names></name><name><surname>Tazi</surname><given-names>MA</given-names></name><name><surname>Bendahmane</surname><given-names>S</given-names></name><name><surname>Bensaoud</surname><given-names>O</given-names></name><name><surname>Benomar</surname><given-names>M</given-names></name></person-group>. <article-title>Prevalence and predictors of white-coat hypertension in a large database of ambulatory blood pressure monitoring.</article-title> <source>East Mediterr Health J</source>. <year>2009</year>;<volume>15</volume>:<fpage>400</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.26719/2009.15.2.400</pub-id><pub-id pub-id-type="pmid">19554987</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangash</surname><given-names>F</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group>. <article-title>Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis.</article-title> <source>Clin J Am Soc Nephrol</source>. <year>2009</year>;<volume>4</volume>:<fpage>656</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.05391008</pub-id><pub-id pub-id-type="pmid">19261815</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Mai</surname><given-names>W</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>An</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group> <article-title>White-coat hypertension is a risk factor for cardiovascular diseases and total mortality.</article-title> <source>J Hypertens</source>. <year>2017</year>;<volume>35</volume>:<fpage>677</fpage>&#x2013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1097/HJH.0000000000001226</pub-id><pub-id pub-id-type="pmid">28253216</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheppach</surname><given-names>JB</given-names></name><name><surname>Raff</surname><given-names>U</given-names></name><name><surname>Toncar</surname><given-names>S</given-names></name><name><surname>Ritter</surname><given-names>C</given-names></name><name><surname>Klink</surname><given-names>T</given-names></name><name><surname>St&#x00F6;rk</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.</article-title> <source>Hypertension</source>. <year>2018</year>;<volume>72</volume>:<fpage>929</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.11608</pub-id><pub-id pub-id-type="pmid">30354716</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>C</given-names></name><name><surname>Pereira</surname><given-names>S</given-names></name><name><surname>Fernandes</surname><given-names>JC</given-names></name><name><surname>Dias</surname><given-names>VP</given-names></name></person-group>. <article-title>24-hour ambulatory blood pressure monitoring in chronic kidney disease and its influence on treatment.</article-title> <source>Port J Nephrol Hypert.</source> <year>2017</year>;<volume>31</volume>:<fpage>31</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>RM</given-names></name><name><surname>Calhoun</surname><given-names>DA</given-names></name><name><surname>Bell</surname><given-names>EK</given-names></name><name><surname>Bowling</surname><given-names>CB</given-names></name><name><surname>Guti&#x00E9;rrez</surname><given-names>OM</given-names></name><name><surname>Irvin</surname><given-names>MR</given-names></name><etal/></person-group> <article-title>Prevalence of apparent treatment-resistant hypertension among individuals with CKD.</article-title> <source>Clin J Am Soc Nephrol</source>. <year>2013</year>;<volume>8</volume>:<fpage>1583</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.00550113</pub-id><pub-id pub-id-type="pmid">23868902</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Andersen</surname><given-names>MJ</given-names></name></person-group>. <article-title>Correlates of systolic hypertension in patients with chronic kidney disease.</article-title> <source>Hypertension</source>. <year>2005</year>;<volume>46</volume>:<fpage>514</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1161/01.HYP.0000178102.85718.66</pub-id><pub-id pub-id-type="pmid">16103271</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Pappas</surname><given-names>MK</given-names></name><name><surname>Sinha</surname><given-names>AD</given-names></name></person-group>. <article-title>Masked uncontrolled hypertension in CKD.</article-title> <source>J Am Soc Nephrol</source>. <year>2016</year>;<volume>27</volume>:<fpage>924</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2015030243</pub-id><pub-id pub-id-type="pmid">26163421</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><etal/></person-group> <article-title>Prognostic Value of Reverse Dipper Blood Pressure Pattern in Chronic Kidney Disease Patients not Undergoing Dialysis: Prospective Cohort Study.</article-title> <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>34932</fpage>. <pub-id pub-id-type="doi">10.1038/srep34932</pub-id><pub-id pub-id-type="pmid">27713498</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>S</given-names></name><name><surname>Garofalo</surname><given-names>C</given-names></name><name><surname>Gabbai</surname><given-names>FB</given-names></name><name><surname>Chiodini</surname><given-names>P</given-names></name><name><surname>Signoriello</surname><given-names>S</given-names></name><name><surname>Paoletti</surname><given-names>E</given-names></name><etal/></person-group> <article-title>Dipping Status, Ambulatory Blood Pressure Control, Cardiovascular Disease, and Kidney Disease Progression: A Multicenter Cohort Study of CKD.</article-title> <source>Am J Kidney Dis</source>. <year>2023</year>;<volume>81</volume>:<fpage>15</fpage>&#x2013;<lpage>24.e1</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2022.04.010</pub-id><pub-id pub-id-type="pmid">35709922</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YT</given-names></name><name><surname>Lampa</surname><given-names>E</given-names></name><name><surname>Fall</surname><given-names>T</given-names></name><name><surname>Engstr&#x00F6;m</surname><given-names>G</given-names></name><name><surname>Sundstr&#x00F6;m</surname><given-names>J</given-names></name></person-group>. <article-title>Blood pressure phenotypes based on ambulatory monitoring in a general middle-aged population.</article-title> <source>Blood Press</source>. <year>2021</year>;<volume>30</volume>:<fpage>237</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1080/08037051.2021.1903302</pub-id><pub-id pub-id-type="pmid">33797315</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tocci</surname><given-names>G</given-names></name><name><surname>Presta</surname><given-names>V</given-names></name><name><surname>Figliuzzi</surname><given-names>I</given-names></name><name><surname>Attalla El Halabieh</surname><given-names>N</given-names></name><name><surname>Battistoni</surname><given-names>A</given-names></name><name><surname>Coluccia</surname><given-names>R</given-names></name><etal/></person-group> <article-title>Prevalence and clinical outcomes of white-coat and masked hypertension: Analysis of a large ambulatory blood pressure database.</article-title> <source>J Clin Hypertens (Greenwich)</source>. <year>2018</year>;<volume>20</volume>:<fpage>297</fpage>&#x2013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1111/jch.13181</pub-id><pub-id pub-id-type="pmid">29370477</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorostidi</surname><given-names>M</given-names></name><name><surname>Vinyoles</surname><given-names>E</given-names></name><name><surname>Banegas</surname><given-names>J</given-names></name><name><surname>de la Sierra</surname><given-names>A</given-names></name></person-group>. <article-title>Prevalence of white-coat and masked hypertension in national and international registries.</article-title> <source>Hypertens Res</source>. <year>2015</year>;<volume>38</volume>:<fpage>1</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/hr.2014.149</pub-id><pub-id pub-id-type="pmid">25319601</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>O</given-names></name><name><surname>Shipman</surname><given-names>KE</given-names></name><name><surname>Day</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>U</given-names></name><name><surname>Dasgupta</surname><given-names>I</given-names></name></person-group>. <article-title>Prevalence and determinants of white coat effect in a large UK hypertension clinic population.</article-title> <source>J Hum Hypertens</source>. <year>2016</year>;<volume>30</volume>:<fpage>386</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1038/jhh.2015.95</pub-id><pub-id pub-id-type="pmid">26377355</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sipahioglu</surname><given-names>NT</given-names></name><name><surname>Sipahioglu</surname><given-names>F</given-names></name></person-group>. <article-title>Closer look at white-coat hypertension.</article-title> <source>World J Methodol</source>. <year>2014</year>;<volume>4</volume>:<fpage>144</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.5662/wjm.v4.i3.144</pub-id><pub-id pub-id-type="pmid">25332913</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Hwu</surname><given-names>I</given-names></name><name><surname>Jacabacci</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name></person-group>. <article-title>The Utility of 24-h Ambulatory Blood Pressure Monitoring for the Diagnosis and Management of White Coat Hypertension in a Primary Care Setting.</article-title> <source>J Prim Care Community Health</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>21501319221123457</elocation-id>. <pub-id pub-id-type="doi">10.1177/21501319221123457</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
